{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-034176","form_type":"8-K","ticker":null,"cik":"0000819050","company_name":"Fresh Tracks Therapeutics, Inc.","filed_at":"2023-10-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.086001+00:00","generated_at":"2026-06-10T03:04:16.295399+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"CEO Sklawer departs; severance includes $441K lump sum, full equity vesting, $425/hr consulting","bullets":["CEO Andrew Sklawer terminated without cause effective Oct 2, 2023; severance of $441k (12 months base) plus $44k retention bonus.","Accrued PTO paid $165,375; health care premiums for 12 months with 35% gross-up if continued coverage not available.","All unvested equity awards fully vested as of Separation Date; equity exercise extended to 3 years.","Sklawer to provide consulting via Yonder Partners at $425 per hour; contract terminable by either party.","CEO departure in connection with previously disclosed plan to liquidate and dissolve the company."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-034176","json":"https://secwatch.observer/filing/0001628280-23-034176.json","markdown":"https://secwatch.observer/filing/0001628280-23-034176.md","text":"https://secwatch.observer/filing/0001628280-23-034176.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/819050/000162828023034176/0001628280-23-034176-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/819050/000162828023034176/frtx-20231003.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T03:04:16.295399+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2040776d34","claim":"Andrew D. Sklawer was terminated as President and Chief Executive Officer at Fresh Tracks Therapeutics, Inc..","evidence_excerpt":"the Company terminated Andrew D. Sklawer, the Company’s President and Chief Executive Officer, without cause, effective October 2, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/819050/000162828023034176/0001628280-23-034176-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}